Situgen Med

Company Overview

Snapshot

Founded in January 2006 by Miki Shacham, Situgen Med operates with 1–10 employees. The company completed clinical trials for its revolutionary umbilical cord blood collection device in September 2008.

Business overview

Situgen Med is a medical device startup focused on developing a comprehensive system for extracting stem-cell-rich umbilical cord blood. The company's core product, the patented SG1040, is a disposable, all-inclusive, and non-contaminating collection kit designed to enhance the quality of cord blood and increase the number of extracted stem cells. This needle-free device addresses bottlenecks associated with traditional collection methods. Situgen Med operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices industry with its innovative medical technologies.

Strategic signal

In September 2008, Situgen Med completed clinical trials for its SG1040 device, a significant milestone validating the efficacy and safety of its umbilical cord blood collection technology. This signals to investors a progression towards market readiness and potential for commercialization within the medical device and stem cell therapy sectors.

Company Intelligence Q&A

What is Situgen Med's primary product?

Situgen Med's primary product is the SG1040, a patented, disposable, and needle-free device designed for the comprehensive and non-contaminating collection of stem-cell-rich umbilical cord blood.

When was Situgen Med founded?

Situgen Med was founded in January 2006.

Who is the founder of Situgen Med?

Miki Shacham is the CEO and founder of Situgen Med.

What significant development occurred in September 2008?

In September 2008, Situgen Med completed clinical trials for its revolutionary device for umbilical cord blood collection.

Which investor participated in Situgen Med's funding round in January 2006?

In January 2006, RAD BioMed participated as an investor in.